Systemic Lupus Erythematosus (SLE) is a multifaceted autoimmune disease that can affect multiple organ systems, with joint involvement being one of its most prevalent manifestations. In many ...

International Journal of Clinical Rheumatology Managing CNS Involvement in Systemic Lupus Erythematosus Matteo Piga; Alessandro Mathieu Disclosures Int J Clin Rheumatol. 2011;6 (5):547-567. 0 ...

The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus (SLE) with extrarenal involvement. The FDA’s ...

Source Reference: Altabás-González I, et al "Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the ...

While the incidence of SLE and lupus nephritis (LN) varies considerably among studies, 5 in general, females outnumber males approximately 10:1, and the peak average age is 15-45 years. Renal ...

TAKEAWAY: At the time of SLE diagnosis, 63.4% of patients presented with gastrointestinal involvement, while others (36.6%) developed gastrointestinal symptoms after a median of 12 months.

ADI-001 was granted Fast Track Designation by the FDA for the treatment of relapsed/refractory class III or class IV lupus nephritis (LN), and SLE with extrarenal involvement.

In a new study, researchers identify biomarkers that may predict the efficacy of low-dose IL-2 (Ld-IL2) treatment in people with systemic lupus erythematosus (SLE). IL-2 stands for interleukin-2 – a ...

The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus (SLE) with extrarenal involvement. The FDA’s ...